Medicare GLP-1 Bridge: $50/Month Coverage Starting July 1, 2026

The Centers for Medicare & Medicaid Services (CMS) has released critical operational updates for its highly anticipated "Medicare GLP-1 Bridge" program. Set to launch on July 1, 2026, and run through December 31, 2027, the temporary demonstration program will offer eligible Medicare beneficiaries access to select obesity medications for a flat copay of $50 per month.

Operations and the Central Processor

In a major structural shift, the Medicare GLP-1 Bridge will operate entirely outside the standard Medicare Part D payment system. CMS will utilize a single central processor to handle prior authorization, claims adjudication, and direct payments to pharmacies.

• No Pharmacy Opt-In Required: Pharmacies do not need to opt in to participate in the program.
• Billing Identifiers: CMS has established a dedicated Bank Identification Number (BIN) and a Processor Control Number (PCN) specific to the Bridge: BIN 028918, PCN MEDDGLP1BR.
• Financial Terms for Pharmacies: Pharmacies will collect the $50 copay from the beneficiary, and the central processor will reimburse the pharmacy at the wholesale acquisition cost (WAC) of the drug, less the copay, plus a dispensing fee and sales tax. This WAC-based reimbursement represents highly favorable financial terms for retail pharmacies.

Covered Medications and Specific NDCs

CMS has defined the exact medications and formulations that will be covered under the Bridge. Notably, the program includes Eli Lilly's newly approved oral small-molecule GLP-1, Foundayo™ (orforglipron), alongside Novo Nordisk's Wegovy® and Lilly's Zepbound®.

The eligible National Drug Codes (NDCs) as of May 2026 are restricted to specific formulations:

1. Foundayo™ (All Formulations): NDCs: 0002-4178-31, 0002-4503-31, 0002-4794-31, 0002-4803-31, 0002-4839-31, 0002-4953-31.
2. Wegovy® (Injection and Tablets): NDCs: 0169-4525-14, 0169-4505-14, 0169-4501-14, 0169-4517-14, 0169-4524-14, 0169-4415-31, 0169-4404-31, 0169-4409-31, 0169-4425-31, 0169-4572-14. (Includes the Wegovy 25 mg oral tablets approved in late 2025).
3. Zepbound® (KwikPen Formulation Only): NDCs: 0002-3566-11, 0002-3555-11, 0002-3544-11, 0002-3533-11, 0002-3522-11, and 0002-3511-11. Note: Single-dose vials and single-dose pens of Zepbound are explicitly excluded from the program.

Beneficiary Eligibility Criteria

To qualify, Medicare beneficiaries must meet specific prior authorization criteria for obesity treatment and be enrolled in an eligible Part D plan type in CY 2026, including:

• Standalone Prescription Drug Plans (PDPs).
• Medicare Advantage Coordinated Care Plans offering drug coverage (MA-PDs, including HMOs and PPOs).
• Special Needs Plans (SNPs) and Employer/Union Group Waiver Plans (EGWPs).
• The Limited Income Newly Eligible Transition (LI NET) program.
• Dually eligible beneficiaries (Medicare/Medicaid) enrolled in eligible Part D plans.

Beneficiaries in private fee-for-service plans, section 1876 cost contract plans, section 1833 health care prepayment plans, PACE organizations, fallback plans, and religious fraternal benefit plans are excluded unless also enrolled in a standalone PDP.

Verbatim Quotes and Interpretation

"Beginning July 1, 2026, all formulations of Foundayo, all formulations of Wegovy, and the KwikPen formulation of Zepbound will be available to eligible beneficiaries through the Medicare GLP-1 Bridge," reported the National Community Pharmacists Association (NCPA) in a clinical alert.

"Pharmacies will collect a $50 copay amount from the eligible beneficiary, and the central processor will process payment to the pharmacy. Pharmacies will be reimbursed by the central processor at the wholesale acquisition cost of a drug, less the beneficiary copay, plus a dispensing fee and, as applicable, sales tax," explained the NCPA operational guidelines.

For healthcare market observers, the Bridge program will act as a major catalyst for retail pharmacy volume and manufacturer revenues in late 2026 and 2027. Because pharmacies are reimbursed at full WAC, the financial friction of dispensing high-cost obesity medications is eliminated, while the $50 copay will trigger an unprecedented wave of patient adoption among Medicare beneficiaries who were previously priced out of the market.